FILING ANALYSIS · THURSDAY, NOVEMBER 12
Cytosorbents Corp CTSO — 8-K: Results of Operations and Financial Condition
neutral
CytoSorbents achieved operating cash flow breakeven in Q3 2026, with revenue growth and improved gross margin, but the overall financial performance is still a net loss, and the cash balance is relatively low at $5.7 million
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →